Skip to content
Top Alliance
Next generation biopharmaceuticals
Top Alliance
  • Home
  • Our Company
    • Our History
    • Our Leadership
    • Our Commitment
  • What we do
    • Discovery
    • Research & Development
    • Manufacturing
  • Our Research
    • Pipeline
    • COVID-19
  • TUOYI®
  • Expanded Access Policy
  • Media
    • News Releases
    • Scientific Publications
    • Company Publications
  • Careers
  • Contact
  • Home
  • Our Company
    • Our History
    • Our Leadership
    • Our Commitment
  • What we do
    • Discovery
    • Research & Development
    • Manufacturing
  • Our Research
    • Pipeline
    • COVID-19
  • TUOYI®
  • Expanded Access Policy
  • Media
    • News Releases
    • Scientific Publications
    • Company Publications
  • Careers
  • Contact

Our Pipeline

Clinical Trial Information

  • Indications: Cancer (FDA breakthrough designation)
  • Clinical trial information:  Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies
  • Indications: COVID-19
  • Clinical trial information: A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness (BLAZE-1)
  • Indications: Cancer (Solid tumors)
  • Clinical trial information:  Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies
  • TopAlliance Biosciences Inc
© TOPALLIANCE BIOSCIENCES - 2023. All rights reserved.

company.info@topalliancebio.com

Go to Top